About 100 reports

The 2019-2024 World Outlook for Insulins and Anti-Diabetic Hormones and Synthetic Substitute Pharmaceuticals ## INTRODUCTION ##. ## OVERVIEW ##. ## WHAT IS LATENT DEMAND AND THE P. I. E.?

  • Antidiabetics
  • Pharmaceutical
  • Therapy
  • World
  • Demand

The 2019-2024 Outlook for Insulins and Anti-Diabetic Hormones and Synthetic Substitute Pharmaceuticals in China ## INTRODUCTION ##. ## OVERVIEW ##. ## WHAT IS LATENT DEMAND AND THE P. I. E.?

  • Antidiabetics
  • Pharmaceutical
  • Therapy
  • China
  • Demand

This influence varies from one industry to another, but also from one period of time to another.

  • Antidiabetics
  • Pharmaceutical
  • Therapy
  • United States
  • Demand

The 2019-2024 Outlook for Insulins and Anti-Diabetic Hormones and Synthetic Substitute Pharmaceuticals in India ## INTRODUCTION ##. ## OVERVIEW ##. ## WHAT IS LATENT DEMAND AND THE P. I. E.?

  • Antidiabetics
  • Pharmaceutical
  • Therapy
  • India
  • Demand

US Antidiabetics Drug Market Outlook 2022 ##.

  • Antidiabetics
  • Chronic Disease
  • Diabetes
  • Insulin
  • United States

RoW other antidiabetics market, by product, 2012 – 2020 (USD Million) List of Figures ##.

  • Antidiabetics
  • Therapy
  • United States
  • Forecast
  • Market Size
  • Forecast for Top Anti-diabetic Molecules
  • Forecast for Top Anti-diabetic Products

Diabetes is a chronic disease in which there are high levels of sugar in the blood. The World Diabetes Foundation estimates that there will be 438 million people with diabetes by the year 2030. Oral anti-diabetics were the leading category of drugs in 2014 and showed a growth rate of 6.3% from the total global sales. The total sales for insulin...

  • Antidiabetics
  • United States
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Takeda Pharmaceutical Company Limited
  • GLOBAL METABOLIC DISORDER DRUGS MARKET, HISTORIC AND FORECAST, SPLIT BY SEGMENTS, 2013-2021
  • Metabolic Disorders Drugs Market Trends And Strategies

Metabolic Disorders Drugs Market Trends And Strategies Development Of New Anti-Diabetic Drugs For Type ## Diabetes - Drug manufacturers are developing various anti-diabetic drugs for type-## diabetes treatment.

  • Antidiabetics
  • World
  • AstraZeneca PLC
  • Horizon Pharma plc
  • Novo Nordisk Group
  • 8.1 References

CoMFA and CoMSIA studies onC-aryl glucoside SGLT## inhibitors as potential anti-diabetic agents.

  • Antidiabetics
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.
  • APIDRA ASSUMPTIONS
  • HUMAN INSULINS (REGULAR/NPH/MIXED) ASSUMPTIONS

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026 Summary Type 2 diabetes (T2D) is a chronic disease characterized by insulin resistance and pancreatic ?-cell failure, with an underlying genetic predisposition heavily influenced by diet and lifestyle (Stumvoll et al., 2010). It is well...

  • Antidiabetics
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Anti-Diabetic Pharmaceuticals Market in India 2015 Slide ##: Executive Summary Macroeconomic Indicators Slide ##: GDP at Factor Cost: Quarterly (2011-## – 2014-##), Inflation Rate: Monthly (Dec 2014-Jan 2015 – Mar 2015-Apr 2015) Slide ##: Gross Fiscal Deficit: Monthly (Feb 2014 – Jul

  • Antidiabetics
  • India
  • Demand
  • Market Size
  • Social Conditions
  • GLOBAL TYPE 2 DIABETES MARKET
  • UNPREDICTABLE OUTCOMES ON HUMAN DUE TO LACK OF PREDICTABLE ANIMAL MODELS

In January 2011, Eli Lilly and Boehringer Ingelheim entered into an agreement covering antidiabetic drugs.

  • Antidiabetics
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Sanofi S.A.

KEY COMPANIES COVERED ##.

  • Antidiabetics
  • Western Europe
  • Forecast
  • Insulet Corporation
  • Medtronic, Inc.

The active ingredient present is liraglutide, which is a GLP-## analog and targets GLP-## receptors.

  • Antidiabetics
  • Diabetes
  • Insulin
  • United States
  • Eli Lilly & Co.
  • FIERCE MARKET COMPETITION
  • Market segmentation by drug class

Trajenta, Jardiance, and Jentadueto were the antidiabetic drugs that had been launched by the alliance.

  • Antidiabetics
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Indian Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics ## Preface ## Research Methodology ## Executive Summary ## Diabetes Disease Overview ##. ## What is Diabetes?

  • Antidiabetics
  • Chronic Disease
  • Diabetes
  • India
  • Market Size
  • Total Insulin Sensitizer Production and Demand (million Yuan)
  • CHAPTER IV DIABETES DRUGS PRODUCTION AND DEMAND

Pioglitazone hydrochloride is an antidiabetic medicine which is used in those people with type ## or non-insulin dependent diabetes (NIDDM).

  • Antidiabetics
  • China
  • GSK China Inc.
  • Novo Nordisk Pharmaceutical Co., Ltd.
  • Zhejiang Expressway Co., Ltd.

##.

  • Antidiabetics
  • Market Size
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Medtronic, Inc.

INTRODUCTION.............. ## ##.

  • Antidiabetics
  • China
  • India
  • World
  • Market Shares

Q. ##.

  • Antidiabetics
  • United States
  • Animas Corporation
  • Becton Property Group
  • Eli Lilly & Co.

##.

  • Antidiabetics
  • East Asia
  • Market Size
  • B. Braun Melsungen AG
  • Eli Lilly & Co.

Its onset of action is ##-## hours.

  • Antidiabetics
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Oramed Pharmaceuticals Inc.
  • Sanofi S.A.

(Hong Kong) ##.

  • Antidiabetics
  • United States
  • World
  • Market Size
  • Supply

Glucagon-like peptide-## (GLP-##) receptor agonists ##. ##. ##. ##.

  • Antidiabetics
  • Therapy
  • APAC
  • World
  • Market Size
  • Total Insulin Sensitizer Production and Demand (million Yuan)
  • CHAPTER IV DIABETES DRUGS PRODUCTION AND DEMAND

The auto exports exceeded over ## million each year.

  • Antidiabetics
  • Diabetes
  • Insulin
  • China
  • Demand
  • ANTI-DIABETIC DRUG CLASSES: HISTORY OF DEVELOPMENT
  • HIGHLIGHTS THE VARIOUS ANTI-DIABETIC DRUG CLASSES AND THE FIRST APPROVED DRUG OF EACH CLASS.

INTRODUCTION Diabetes, considered to be the most common metabolic disorder in humans, is ranked among the top ten fatal diseases in the US. The increasing incidence, growing prevalence and the progressive nature of the disease has spurred several pharmaceutical companies to develop novel approaches / therapies to provide better treatment...

  • Antidiabetics
  • North America
  • United States
  • Boehringer Ingelheim GmbH
  • Sanofi S.A.

Japan Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics ## Preface ## Research Methodology ## Executive Summary ## Introduction ##. ## Overview ##. ## Key Industry Trends ## Diabetes Disease Overview ##. ## What is Diabetes?

  • Antidiabetics
  • Chronic Disease
  • Diabetes
  • Japan
  • Market Size

Around three decades ago, less than one percent of the Chinese adult population had diabetes.

  • Antidiabetics
  • Chronic Disease
  • Diabetes
  • China
  • Market Size

(USA) ##.

  • Antidiabetics
  • United States
  • World
  • Market Shares
  • Supply